Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control. To evaluate the tolerability and safety of SR58611A in patients with GAD.


Clinical Trial Description

The current study will be conducted to evaluate the efficacy, safety, and tolerability of SR58611A (350 mg q12) compared to placebo in patients with generalized anxiety disorder (GAD), using escitalopram (10 mg qd) as a positive control. This is an 8-week, double-blind, randomized, 3-parallel-group, placebo- and escitalopram-controlled, study.A 1-week, placebo, single-blind period precedes the 8-week randomized treatment period. A Safety Follow up Visit (Segment C) is scheduled 1 week after the acute treatmentperiod (Segment B) or early termination. This trial is designed to compare the efficacy, safety, and tolerability of SR58611A to placebo. In this study, escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, is used as a positive control and has been chosen as the comparator agentas it is approved for treatment of GAD at a dose of 10 mg once daily. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00252343
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 3
Start date September 2005
Completion date February 2007

See also
  Status Clinical Trial Phase
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Not yet recruiting NCT03224845 - Courageous Parents, Courageous Children N/A
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Completed NCT02145429 - Preventing Depression in Late Life: A Model for Low and Middle Income Countries N/A
Completed NCT00794456 - Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety Phase 3
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Not yet recruiting NCT05867823 - OcupApp: Occupational Self-analysis Intervention Through an Mobile Application N/A
Recruiting NCT04562324 - Efficacy of Electroencephalography (EEG) Neurofeedback (NF) for the Treatment of Anxiety Disorder N/A
Recruiting NCT05989451 - Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders N/A
Not yet recruiting NCT05488418 - Clinical Study of Biomarkers of Stress Resilience: Role of ELK1 and GPR56 N/A
Not yet recruiting NCT03608449 - Doing More With Less": Optimizing Psychotherapeutic Services in the Mental Health System N/A
Completed NCT03400397 - An Effectiveness Study of the Cool Kids Programme N/A
Completed NCT00025844 - Fear Conditioning Using Computer-Generated Virtual Reality N/A
Completed NCT02579928 - Ketamine Infusion for Adolescent Depression and Anxiety Phase 4
Completed NCT02270073 - The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Completed NCT01425619 - The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests N/A
Completed NCT01721824 - The Effect of IPS-MA- A Modified Early Supported Employment Intervention for Individuals With Mood or Anxiety Disorders N/A
Completed NCT01227980 - Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^ Phase 2
Completed NCT01730625 - Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial N/A